🇺🇸 FDA

Intelligence · Clinical Pipeline

Lakefront Biotherapeutics NV Pipeline

All ClinicalTrials.gov programs at Lakefront Biotherapeutics NV — phase, modality, and trial IDs.

Programs
99

Quick answer

Lakefront Biotherapeutics NV has 99 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Filgotinib

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  2. Filgotinib

    Lakefront Biotherapeutics NV

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials

  3. Filgotinib

    Lakefront Biotherapeutics NV

    Ankylosing Spondylitis

    phase 3 small molecule terminated

    3 trials

  4. Filgotinib

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials

  5. GLPG CAR T-cell therapy

    Lakefront Biotherapeutics NV

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial

  6. GLPG1690

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

  7. Filgotinib

    Lakefront Biotherapeutics NV

    Small Bowel Crohn's Disease

    phase 2 small molecule completed

    1 trial

  8. Filgotinib

    Lakefront Biotherapeutics NV

    Inflammatory Bowel Disease

    phase 2 small molecule terminated

    1 trial

  9. Filgotinib

    Lakefront Biotherapeutics NV

    Fistulizing Crohn's Disease

    phase 2 small molecule completed

    1 trial

  10. Filgotinib

    Lakefront Biotherapeutics NV

    Noninfectious Uveitis

    phase 2 small molecule terminated

    1 trial

  11. GLPG0259 oral capsule

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  12. GLPG0634

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  13. GLPG0634

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    4 trials

  14. GLPG0974

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  15. GLPG1205

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  16. GLPG1205

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  17. GLPG1690

    Lakefront Biotherapeutics NV

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  18. GLPG1690 600 mg QD

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  19. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  20. GLPG1972

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  21. GLPG2222 150 mg q.d.

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  22. GLPG2222 50 mg

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  23. GLPG2737

    Lakefront Biotherapeutics NV

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  24. GLPG2737

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  25. GLPG3667

    Lakefront Biotherapeutics NV

    Dermatomyositis

    phase 2 small molecule completed

    1 trial

  26. GLPG3667

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  27. GLPG3970

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  28. GLPG3970

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  29. GLPG3970

    Lakefront Biotherapeutics NV

    Primary Sjögren Syndrome

    phase 2 small molecule terminated

    1 trial

  30. GLPG5101

    Lakefront Biotherapeutics NV

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 gene therapy active

    1 trial

  31. Lanraplenib

    Lakefront Biotherapeutics NV

    Sjogren's Syndrome

    phase 2 small molecule completed

    1 trial

  32. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  33. MOR 106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  34. MOR106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  35. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  36. 100 mg GLPG1205

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  37. 100 mg dose of [14C] GLPG0634

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  38. 200 mg GLPG0634 as capsules, fasted

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  39. 500 mg GLPG1837 as oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  40. Atorvastatin

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  41. Filgotinib

    Lakefront Biotherapeutics NV

    Bioavailability

    phase 1 small molecule completed

    1 trial

  42. GLPG0187

    Lakefront Biotherapeutics NV

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  43. GLPG0187

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  44. GLPG0187 prodrug

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  45. GLPG0259

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  46. GLPG0259 fumarate

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  47. GLPG0259 solution

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  48. GLPG0492

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

Frequently asked questions

How many pipeline programs does Lakefront Biotherapeutics NV have?

99 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.